Product

Hikma receives FDA approval for Rifampin Injection

London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Rifampin Injection USP, 600mg/vial has been approved by the U.S. Food and Drug Administration (“FDA”)

Rifampin Injection is an anti-infective indicated to treat certain infections such as tuberculosis and leprosy. According to IMS Health, sales of Rifampin Injection in the US market were approximately $14.3 million for the 12 months ending January 2016.